Spots Global Cancer Trial Database for Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer

Official Title: A Phase 1 Study of Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer Before or After Progression on Docetaxel.

Study ID: NCT02207504

Conditions

Castration-resistant Prostate Cancer

Interventions

Crizotinib

Enzalutamide

Study Description

Brief Summary: This research study is comparing the combination of drugs Crizotinib and Enzalutamide as a possible treatment for metastatic castration-resistant prostate cancer (mCRPC).

Detailed Description: * A traditional 3+3 dose escalation scheme will be used to identify the recommended phase 2 dose (RP2D) of crizotinib when used in combination with standard fixed dose enzalutamide. * Patients who fulfill eligibility criteria will be entered into the trial to receive crizotinib and enzalutamide. * After the screening procedures confirm participation in the research study: * The participant will be given a study drug-dosing calendar for each treatment cycle. The investigators are looking for the highest dose of the combination of study drugs that can be administered safely without severe or unmanageable side effects in participants that have, not everyone who participates in this research study will receive the same dose of the study drug. The dose given will depend on the number of participants who have been enrolled in the study prior and how well the dose was tolerated.